Pediatric Oncology

Hodgkin Lymphoma

Questions discussed in this category

What is your first line of therapy for refractory Hodgkin lymphoma in an AYA patient?

1 Answer available

How do you define bulky disease for Hodgkin's lymphoma which is outside the mediastinum?

Do you use a cutoff of 10 cm? Do you measure the size of the largest node or measure the largest conglomerate or measure the total length of the entir...

1 Answer available

How do you interpret a Deauville score of 3 on PET when performing mid-treatment assessments in patients with Hodgkin lymphoma?

Are there situations in which a Deauville 3 would cause you to escalate therapy?

2 Answers available

How would you treat a young patient with classical intermediate-risk Hodgkin lymphoma who has an underlying DNA repair-deficiency disorder, such as congenital mismatch repair disorder or ataxia telangiectasia?

How does your treatment approach vary depending on the underlying predisposition?

1 Answer available

How long should patients treated with frontline therapy for Hodgkin lymphoma wait before attempting to conceive a child?

Do your recommendations differ between those who receive ABVD and escalated BEACOPP? Do you recommend consultation with fertility specialists for all...

1 Answer available

Do you think there is any compelling data to support giving brentuximab as frontline therapy for pediatric patients with Hodgkin lymphoma?

Results of AHOD1331 are not yet known, but adults have started using Brentuximab upfront for high risk patients

1 Answer available

What is the preferred treatment approach for an AYA patient with intermediate to high risk Hodgkin lymphoma: The pediatric approach (ABVE-PC +/- radiation) or the adult approach (ABVD with possible escalation to BEACOPP)?

1 Answer available

When do you consider including Rituximab into the treatment regimen for a pediatric or AYA patient with intermediate and advanced-stage nodular lymphocyte-predominant Hodgkin lymphoma?

1 Answer available

Is dexrazoxane recommended for cardioprotection in AYA patients with Hodgkin lymphoma who are receiving anthracyclines as part of their upfront therapy?

3 Answers available

For AYA patients with early-stage Hodgkin's lymphoma being treated with ABVD, how many cycles of chemotherapy do you administer, and when can radiation be avoided?

Have the RAPID or CALGB 5064 studies changed your treatment approach?

2 Answers available

What treatment would you recommend to effectively treat a pediatric patient newly diagnosed with low risk Hodgkin's lymphoma while minimizing the risk of late toxicity?

1 Answer available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-11-10

Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031.

N. Engl. J. Med., 2015-04-23

Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

J. Clin. Oncol., 2019 Sep 10

Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.

Blood, 2018 Sep 6

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.

J Clin Oncol, 2017 Mar 14

Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-20

Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.

J Clin Oncol, 2020 Apr 28

Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Blood, 2009-09-03

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.

N. Engl. J. Med., 2018-01-25

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

J Clin Oncol, 2021 Apr 07

Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.

Clin Transl Oncol, 2020 Sep 17

ABVD and BEACOPP regimens' effects on fertility in young males with Hodgkin lymphoma.

J Assist Reprod Genet, 2020 Jun 02

Impact of ABVD chemotherapy on ovarian reserve after fertility preservation in reproductive-aged women with Hodgkin lymphoma.

Lancet Oncol, 2018 Sep 13

Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.

British journal of haematology, 2014-06

F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.

International journal of radiation oncology, biology, physics, 2019-06-01

Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology, 2007-04

Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.

Blood, 2018-07-05

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

Blood,

Getting to transplant in Hodgkin lymphoma: BVB.

Blood,

Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.

J Clin Oncol, 2021 Jun 25

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-09-20

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Blood, 2016-11-24

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

Lancet, 2012 Apr 04

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

Blood, 2018 Aug 30

Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.

Ann Oncol,

Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma.

Related Topics in Pediatric Oncology